Protalix BioTherapeutics Inc logo

Protalix BioTherapeutics Inc

1
AMEX:PLX (USA)  
$ 1.27 -0.06 (-4.51%) 11:08 PM EST
63.50
P/B:
2.76
Market Cap:
$ 92.78M
Enterprise V:
$ 78.75M
Volume:
696.54K
Avg Vol (2M):
322.81K
Also Trade In:
Volume:
696.54K
Avg Vol (2M):
322.81K

Business Description

Description
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Name Current Vs Industry Vs History
Cash-To-Debt 1.7
Equity-to-Asset 0.4
Debt-to-Equity 0.78
Debt-to-EBITDA 2.03
Interest Coverage 3.28
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.6
Distress
Grey
Safe
Beneish M-Score -1.28
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 22.05
9-Day RSI 29.56
14-Day RSI 34.47
6-1 Month Momentum % -15.03
12-1 Month Momentum % -27.59

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.54
Quick Ratio 1.12
Cash Ratio 0.98
Days Inventory 309.29
Days Sales Outstanding 26.91
Days Payable 68.94

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -28
Shareholder Yield % -19.23

Financials (Next Earnings Date:2024-05-03 Est.)

PLX's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with AMEX:PLX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Protalix BioTherapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 65.494
EPS (TTM) ($) 0.02
Beta -0.28
Volatility % 62.12
14-Day RSI 34.47
14-Day ATR ($) 0.078077
20-Day SMA ($) 1.473
12-1 Month Momentum % -27.59
52-Week Range ($) 1.21 - 3.55
Shares Outstanding (Mil) 73.05

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Protalix BioTherapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Protalix BioTherapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Protalix BioTherapeutics Inc Frequently Asked Questions

What is Protalix BioTherapeutics Inc(PLX)'s stock price today?
The current price of PLX is $1.27. The 52 week high of PLX is $3.55 and 52 week low is $1.21.
When is next earnings date of Protalix BioTherapeutics Inc(PLX)?
The next earnings date of Protalix BioTherapeutics Inc(PLX) is 2024-05-03 Est..
Does Protalix BioTherapeutics Inc(PLX) pay dividends? If so, how much?
Protalix BioTherapeutics Inc(PLX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1